Lucid Diagnostics (NASDAQ:LUCD) Stock Rating Reaffirmed as “Buy” by BTIG Research

Posted by Brenda Bartman on Oct 23rd, 2026

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a report issued on Friday, Benzinga reports.

Several other analysts also recently issued reports on LUCD. Needham & Company LLC reissued a “buy” rating on shares of Lucid Diagnostics in a research note on Thursday, October 1st. Weiss Ratings downgraded shares of Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. Finally, Wall Street Zen downgraded shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lucid Diagnostics has a consensus rating of “Moderate Buy” and a consensus price target of $4.19.

Check Out Our Latest Stock Analysis on LUCD

Lucid Diagnostics Trading Up 25.4%

NASDAQ:LUCD traded up $0.08 during trading hours on Friday, hitting $0.41. 110,807,221 shares of the stock traded hands, compared to its average volume of 2,113,805. The firm has a 50 day moving average price of $0.77 and a 200 day moving average price of $0.95. Lucid Diagnostics has a fifty-two week low of $0.30 and a fifty-two week high of $1.63. The firm has a market cap of $83.53 million, a price-to-earnings ratio of -0.87 and a beta of 1.12.

Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $1.47 million for the quarter, compared to analyst estimates of $1.43 million. Research analysts predict that Lucid Diagnostics will post -0.23 EPS for the current year.

Institutional Investors Weigh In On Lucid Diagnostics

Large investors have recently bought and sold shares of the business. Pine Valley Investments Ltd Liability Co boosted its holdings in Lucid Diagnostics by 73.2% in the first quarter. Pine Valley Investments Ltd Liability Co now owns 34,283 shares of the company’s stock worth $39,000 after purchasing an additional 14,487 shares in the last quarter. Two Sigma Securities LLC bought a new stake in Lucid Diagnostics in the second quarter worth $43,000. Bank of America Corp DE boosted its holdings in Lucid Diagnostics by 25.9% in the first quarter. Bank of America Corp DE now owns 88,527 shares of the company’s stock worth $102,000 after purchasing an additional 18,212 shares in the last quarter. Sequoia Financial Advisors LLC bought a new stake in Lucid Diagnostics in the second quarter worth $99,000. Finally, State of Wyoming bought a new stake in Lucid Diagnostics in the second quarter worth $101,000. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Company Profile

(Get Free Report)

Lucid Diagnostics Inc is a commercial-stage medical diagnostics company focused on detecting esophageal precancer and cancer at an earlier, more treatable stage. The company is a subsidiary of PAVmed Inc and develops diagnostic products intended to help identify patients at risk for esophageal adenocarcinoma, a cancer associated with Barrett’s esophagus and chronic gastroesophageal reflux disease.

Lucid’s primary products are EsoGuard, a laboratory-developed DNA test, and EsoCheck, a noninvasive, swallowable balloon device used to collect cells from the esophagus.